Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast.

logo will not comply with upcoming new requirements ... leading many municipalities and brands to no longer use it. “Ensuring accessibility is about equity and inclusion,” Gauvin said.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

🖼️ Image Toolbox is a powerful app for advanced image manipulation. It offers dozens of features, from basic tools like crop and draw to filters, OCR, and a wide range of image processing options ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

You pay a one-off fee per logo, the price of which varies depending on the features you require (such as a transparent background or social media designs), and if you need the ability to amend ...

Novartis AG’s plan to sell its 70.6% stake in Novartis India is on track, CEO Vas Narasimhan confirmed at the World Economic Forum in Davos. Speaking to CNBC-TV18, he emphasised the company’s ...

Greece on Monday prosecuted a pair of protected witnesses for alleged perjury in a long-running bribery probe involving the Swiss pharmaceutical firm Novartis, a justice source said. The man and woman ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...

TIN-816 is under clinical development by Novartis and currently in Phase II for Sepsis. According to GlobalData, Phase II drugs for Sepsis have a 50% phase transition success rate (PTSR) indication ...

Entresto’s importance to Novartis is illustrated in the company’s most recent quarterly report, which revealed that the drug generated $5.6 billion in the first three quarters of 2024 ...

Novartis (NVS) has filed a lawsuit accusing the Biden administration of unlawfully preventing the company from changing payment terms to some hospitals that participate in the 340B Drug Discount ...